Communicating cancer risk from radiation exposures: Nuclear accidents, total body radiation and diagnostic procedures

摘要

Invasive mold infections (IMIs) can complicate intensive myelo-suppressive chemotherapy for hematological malignancies, particularly acute leukemia. As allogeneic hematopoietic SCT (HSCT) is often the only curative treatment for the majority of these patients, clinicians often encounter the therapeutic dilemma of balancing further cytotoxic therapy and HSCT with the risk of IMl relapse-related morbidity and death. Although improvements in diagnosis and the introduction of new antifungal agents have improved prognosis for IMIs, the possibility of post-transplant IMl relapse is considerable and historically associated with poor outcomes.